38 results on '"Poluru L. Reddy"'
Search Results
2. Data from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
- Author
-
Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Walter M. Stadler, L. Austin Doyle, Scott E. Smith, Sachdev P. Thomas, Philip Dy, Ehab L. Atallah, Loren Joseph, Poluru L. Reddy, Kevin Shannon, Greg Koval, Xavier Poire, Margaret Green, Harry P. Erba, Theodore Karrison, Mark H. Kirschbaum, Leslie Popplewell, Rangesh Kunnavakkam, Ernesto Diaz-Flores, Neil M. Iyengar, Emily Curran, and Nitin Jain
- Abstract
Purpose: The clinical relevance of targeting the RAS/RAF/MEK/ERK pathway, activated in 70% to 80% of patients with acute myelogenous leukemia (AML), is unknown.Experimental Design: Selumetinib is an oral small-molecule inhibitor of MAP–ERK kinase (MEK)-1/2. Forty-seven patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study. Patients were stratified by FLT3 ITD mutation status. The primary endpoint was response rate (complete, partial, and minor). Leukemia cells were analyzed for extracellular signal—regulated kinase (ERK) and mTOR phosphorylation.Results: Common drug-related toxicities were grade 1–2 diarrhea, fatigue, nausea, vomiting, and skin rash. In the FLT3 wild-type cohort, six of 36 (17%) patients had a response [one partial response, three minor responses, two unconfirmed minor responses (uMR)]. No patient with FLT3 ITD responded. NRAS and KRAS mutations were detected in 7% and 2% of patients, respectively. The sole patient with KRAS mutation had uMR with hematologic improvement in platelets. Baseline p-ERK activation was observed in 85% of patients analyzed but did not correlate with a response. A single-nucleotide polymorphism (SNP) rs3733542 in exon 18 of the KIT gene was detected in significantly higher number of patients with response/stable disease compared with nonresponders (60% vs. 23%; P = 0.027).Conclusions: Selumetinib is associated with modest single-agent antileukemic activity in advanced AML. However, given its favorable toxicity profile, combination with drugs that target other signaling pathways in AML should be considered. The potential association of SNP rs3733542 in exon 18 of the KIT gene with antileukemic activity of selumetinib is intriguing, but will require validation in larger trials. Clin Cancer Res; 20(2); 490–8. ©2013 AACR.
- Published
- 2023
3. Supplementary Table 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
- Author
-
Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Walter M. Stadler, L. Austin Doyle, Scott E. Smith, Sachdev P. Thomas, Philip Dy, Ehab L. Atallah, Loren Joseph, Poluru L. Reddy, Kevin Shannon, Greg Koval, Xavier Poire, Margaret Green, Harry P. Erba, Theodore Karrison, Mark H. Kirschbaum, Leslie Popplewell, Rangesh Kunnavakkam, Ernesto Diaz-Flores, Neil M. Iyengar, Emily Curran, and Nitin Jain
- Abstract
PDF file - 50K, Primers for KIT gene mutation testing.
- Published
- 2023
4. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy
- Author
-
Maria Luisa Carcangiu, Madhavi Nagilla, Laura D. Locati, Poluru L. Reddy, Tanguy Y. Seiwert, Ezra E.W. Cohen, Giuseppe Pelosi, Rebecca B. Schechter, Sydeaka Watson, Arun Khattri, Loren Joseph, Lisa Licitra, Angela Greco, and Mark W. Lingen
- Subjects
Adult ,Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,Indazoles ,Axitinib ,DNA Copy Number Variations ,Class I Phosphatidylinositol 3-Kinases ,DNA Mutational Analysis ,Antineoplastic Agents ,Biology ,medicine.disease_cause ,Polymorphism, Single Nucleotide ,Radiation Tolerance ,Iodine Radioisotopes ,Phosphatidylinositol 3-Kinases ,medicine ,Humans ,Thyroid Neoplasms ,HRAS ,Progression-free survival ,Thyroid cancer ,Genetic Association Studies ,Aged ,Aged, 80 and over ,Vascular Endothelial Growth Factor Receptor-1 ,Genetic heterogeneity ,Gene Amplification ,Imidazoles ,Middle Aged ,Vascular Endothelial Growth Factor Receptor-3 ,medicine.disease ,Vascular Endothelial Growth Factor Receptor-2 ,Carcinoma, Papillary ,Exact test ,Oncology ,Cancer research ,Immunohistochemistry ,Female ,KRAS ,Drug Screening Assays, Antitumor ,Radiopharmaceuticals ,medicine.drug - Abstract
Biomarkers predicting which patients with advanced radioiodine-resistant differentiated thyroid cancer (DTC) may benefit from multi-kinase inhibitors are unavailable. We aimed to describe molecular markers in DTC that correlate with clinical outcome to axitinib. Pretreatment thyroid cancer blocks from 18 patients treated with axitinib were collected and genomic DNA was isolated. The OncoCarta™ Mutation Panel was used to test for 238 oncogenic mutations. Copy number of VEGFR1-3 and PIK3CA was determined using qPCR on enriched tumor samples. Genomic DNA was analyzed for all coding regions of VEGFR1-3 with custom primers. Protein expressions of VEGFR1-3, c-Met, and PIK3CA were evaluated with immunohistochemistry. Clinical response to axitinib, including best response (BR) and progression free survival (PFS), was ascertained from corresponding patients. Fisher's exact test and logistic regression models were used to correlate BR with molecular findings. Cox proportional hazards regression was used to correlate PFS with molecular defects. A total of 22 pathology samples (10 primary, 12 metastatic) were identified. In patients with 2 samples (n = 4), genetic results were concordant and only included once for analysis. Tumors from 4 patients (22%) harbored BRAF V600E mutations, 2 (11%) had KRAS mutations (G12A, G13D) and 2 (11%) had HRAS mutations (Q61R, Q61K). One metastatic sample with mutated KRAS also harbored a PIK3CA (H1047R) mutation. qPCR showed increased copy numbers of PIK3CA in 6 (33%) tumors, VEGFR1 in 0 (0%) tumors, VEGFR2 in 4 (22%) tumors, and VEGFR3 in 6 (33%) tumors. VEGFR sequencing was significant for a possibly damaging non-synonymous SNP in VEGFR2 (G539R) in 2 samples (11%), a possibly damaging SNP in VEGFR3 (E350V) in 1 sample (6%), and a potentially novel mutation in VEGFR2 (T439I) in 2 samples (11%). Immunohistochemistry (VEGFR1, -2, -3; c-MET; PIK3CA) revealed positive staining in the majority of samples. No significant relationship was seen between BR or PFS and the presence of molecular alterations. Molecular evaluation of DTC specimens did not predict clinical response to axitinib but our data were limited by sample size. We did identify molecular changes in VEGFR that should be further explored. While DTC is genetically heterogeneous, primary and metastatic lesions showed identical oncogenic alterations in four cases.
- Published
- 2015
5. Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: Characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays
- Author
-
Madina Sukhanova, Gerhard Ehninger, Poluru L. Reddy, Wendy Stock, Klaus Zöphel, Friedrich Stölzel, Loren Joseph, Gordana Raca, Friederike Kuithan, M. Kamran Mirza, Kenan Onel, and Richard A. Larson
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Pathology ,Tissue Fixation ,Biology ,Article ,Bone Marrow ,Formaldehyde ,Complex Karyotype ,medicine ,Myeloid sarcoma ,Humans ,Sarcoma, Myeloid ,Aged ,Chromosome Aberrations ,Multiple abnormalities ,Paraffin Embedding ,Microarray analysis techniques ,Cytogenetics ,Myeloid leukemia ,Hematology ,Middle Aged ,Microarray Analysis ,medicine.disease ,medicine.anatomical_structure ,Oncology ,Cytogenetic Analysis ,Female ,Bone marrow ,DNA microarray - Abstract
Myeloid sarcoma (MS) is a presentation of acute myeloid leukemia (AML) as a tumor mass outside of the bone marrow. Viable cells from MS are frequently unavailable for cytogenetic studies. We therefore investigated whether chromosomal microarray analysis (CMA) using formalin-fixed paraffin-embedded (FFPE) tissues can detect clinically important genetic abnormalities in MS. CMA successfully identified genomic aberrations in six cases of MS, and in two cases it revealed multiple abnormalities equivalent to a complex karyotype, thus predicting a poor outcome. CMA using FFPE material is therefore a feasible and clinically applicable approach for detection of prognostically significant genomic abnormalities in MS.
- Published
- 2014
6. Multiplexed Quantification of Nucleic Acids with Large Dynamic Range Using Multivolume Digital RT-PCR on a Rotational SlipChip Tested with HIV and Hepatitis C Viral Load
- Author
-
Feng Shen, Bing Sun, Jason E. Kreutz, Wenbin Du, Loren Joseph, Poluru L. Reddy, Rustem F. Ismagilov, and Elena K. Davydova
- Subjects
Rotation ,Reverse Transcriptase Polymerase Chain Reaction ,Dynamic range ,Chemistry ,HIV ,RNA ,Hepacivirus ,General Chemistry ,Hepatitis C ,Microfluidic Analytical Techniques ,Viral Load ,medicine.disease ,Biochemistry ,Virology ,Molecular biology ,Multiplexing ,Article ,Catalysis ,Colloid and Surface Chemistry ,Real-time polymerase chain reaction ,Wide dynamic range ,Nucleic acid ,medicine ,RNA, Viral ,Viral load - Abstract
In this paper, we are working toward a problem of great importance to global health: determination of viral HIV and hepatitis C (HCV) loads under point-of-care and resource limited settings. While antiretroviral treatments are becoming widely available, viral load must be evaluated at regular intervals to prevent the spread of drug resistance and requires a quantitative measurement of RNA concentration over a wide dynamic range (from 50 up to 10(6) molecules/mL for HIV and up to 10(8) molecules/mL for HCV). "Digital" single molecule measurements are attractive for quantification, but the dynamic range of such systems is typically limited or requires excessive numbers of compartments. Here we designed and tested two microfluidic rotational SlipChips to perform multivolume digital RT-PCR (MV digital RT-PCR) experiments with large and tunable dynamic range. These designs were characterized using synthetic control RNA and validated with HIV viral RNA and HCV control viral RNA. The first design contained 160 wells of each of four volumes (125 nL, 25 nL, 5 nL, and 1 nL) to achieve a dynamic range of 5.2 × 10(2) to 4.0 × 10(6) molecules/mL at 3-fold resolution. The second design tested the flexibility of this approach, and further expanded it to allow for multiplexing while maintaining a large dynamic range by adding additional wells with volumes of 0.2 nL and 625 nL and dividing the SlipChip into five regions to analyze five samples each at a dynamic range of 1.8 × 10(3) to 1.2 × 10(7) molecules/mL at 3-fold resolution. No evidence of cross-contamination was observed. The multiplexed SlipChip can be used to analyze a single sample at a dynamic range of 1.7 × 10(2) to 2.0 × 10(7) molecules/mL at 3-fold resolution with limit of detection of 40 molecules/mL. HIV viral RNA purified from clinical samples were tested on the SlipChip, and viral load results were self-consistent and in good agreement with results determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test. With further validation, this SlipChip should become useful to precisely quantify viral HIV and HCV RNA for high-performance diagnostics in resource-limited settings. These microfluidic designs should also be valuable for other diagnostic and research applications, including detecting rare cells and rare mutations, prenatal diagnostics, monitoring residual disease, and quantifying copy number variation and gene expression patterns. The theory for the design and analysis of multivolume digital PCR experiments is presented in other work by Kreutz et al.
- Published
- 2011
7. Remicade as TNF Suppressor in Patients with Myelodysplastic Syndromes
- Author
-
A Candoni, Parameswaran Venugopal, Azra Raza, U Khan, Sefer Gezer, M Imran Alvi, S Tahir, Muhammad Waseem Mumtaz, F Silvestri, L Lisak, Naomi Galili, J Billmeier, and Poluru L. Reddy
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Combination therapy ,Pancytopenia ,medicine.drug_class ,Pilot Projects ,Remicade ,Monoclonal antibody ,Gastroenterology ,Stable Disease ,Internal medicine ,medicine ,Humans ,Myelodysplastic syndromes (MDS) ,In patient ,Aged ,Chromosome Aberrations ,Tumor necrosis factor alpha ,Tumor Necrosis Factor-alpha ,business.industry ,Myelodysplastic syndromes ,Anemia, Refractory ,Remission Induction ,Antibodies, Monoclonal ,Hematology ,medicine.disease ,Infliximab ,Treatment Outcome ,Oncology ,Myelodysplastic Syndromes ,Cytogenetic Analysis ,Cohort ,Immunology ,Disease Progression ,Patient Compliance ,Female ,Hemoglobin ,business - Abstract
Remicade, a chimeric human-murine monoclonal antibody capable of neutralizing tumor necrosis factor alpha was given to 37 low-risk myelodysplastic syndromes (MDS) patients in two cohorts; 5 and 10 mg/kg intravenously every 4 weeks for 4 cycles. Median age was 68 years, 33 had primary MDS, 14 had refractory anemia (RA), 14 RA with ringed sideroblasts, 9 RA with excess blasts. Nine patients stopped therapy prior to completing 4 cycles, 3 from cohort 1 and 6 from cohort 2 and response was evaluated using the International Working Group criteria in 28 patients who completed the 4 cycles. Six patients showed disease progression, 14 had stable disease and 8 showed hematologic responses, 3/15 (20%) in cohort 1 and 5/13 (38%) in cohort 2. Two patients had multi-lineage responses, 2 had > 100% increase in absolute neutrophils, I had > 1 gm/dl increase in hemoglobin, I had reduction in blasts from 7% to 1%, and 2 had minor cytogenetic responses ( > 50% reduction in + 8 and 20q-metaphases respectively). We conclude that Remicade may have a variety of activities in low risk MDS patients, is well tolerated with a high patient compliance, and may be considered for combination therapy in the future.
- Published
- 2004
8. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression
- Author
-
J.Alejandro Gallegos, Hassan Pervaiz, Poluru L. Reddy, Nusrat Ijaz Chaudary, Sefer Gezer, Azra Raza, Silvia Buonamici, Jack W. Singer, Naomi Galili, Giuseppina Nucifora, Donglan Li, Parameswaran Venugopal, Muhammad Mumtaz, M Imran Alvi, Mehnaz Imran, Laurie Lisak, Sarah Tahir, and Anna Candoni
- Subjects
Male ,Oncology ,Cancer Research ,Drug resistance ,Arsenicals ,chemistry.chemical_compound ,Arsenic Trioxide ,Risk Factors ,Talidomide ,Neoplasm ,Agiogenesis ,Aoptosis ,Asenic trioxide ,EVI1 ,Melodysplastic syndromes ,Arsenic trioxide ,Reverse Transcriptase Polymerase Chain Reaction ,Oxides ,Zinc Fingers ,Hematology ,Middle Aged ,Thalidomide ,DNA-Binding Proteins ,medicine.anatomical_structure ,Drug Therapy, Combination ,Female ,Immunosuppressive Agents ,medicine.drug ,medicine.medical_specialty ,Antineoplastic Agents ,Spleen ,Pharmacotherapy ,Internal medicine ,Proto-Oncogenes ,medicine ,Humans ,Cell Lineage ,Aged ,business.industry ,Myelodysplastic syndromes ,medicine.disease ,MDS1 and EVI1 Complex Locus Protein ,In vitro ,chemistry ,Drug Resistance, Neoplasm ,Myelodysplastic Syndromes ,Immunology ,business ,Transcription Factors - Abstract
Twenty-eight myelodysplastic syndromes (MDS) patients were treated with arsenic trioxide (ATO) and thalidomide. Seven patients responded including one complete hematologic and cytogenetic response and one with regression in spleen size. Two trilineage responses were seen in patients with inv(3)(q21q26.2). Three of five patients who had high pre-therapy EVI1 levels showed unexpectedly good responses while two died early in the first cycle. In vitro studies using 32Dcl3 cells forced to express EVI1 confirmed increased sensitivity of these cells to ATO. Both low/high risk MDS may benefit significantly from therapy with ATO/thalidomide, and those with high pre-therapy EVI1 expression may be uniquely sensitive.
- Published
- 2004
9. Biological Significance of Proliferation, Apoptosis, Cytokines, and Monocyte/Macrophage Cells in Bone Marrow Biopsies of 145 Patients With Myelodysplastic Syndrome
- Author
-
Howard M. Kravitz, Azra Raza, Shalini Anthwal, Gurveen Saberwal, Diya Dutt, Poluru L. Reddy, Suneel D. Mundle, Vilasini Shetty, Aaron York, Krishnan Allampallam, Naomi Galili, Maliha Shaikh, and Sairah Alvi
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Apoptosis ,Bone Marrow Cells ,Monocytes ,S Phase ,Transforming Growth Factor beta ,Internal medicine ,Animals ,Humans ,Medicine ,Macrophage ,Anemia, Refractory, with Excess of Blasts ,Hematology ,Tumor Necrosis Factor-alpha ,business.industry ,Macrophages ,Monocyte ,Myelodysplastic syndromes ,Growth factor ,Anemia, Refractory ,Leukemia, Myelomonocytic, Chronic ,medicine.disease ,medicine.anatomical_structure ,Cytokine ,Myelodysplastic Syndromes ,Immunology ,Cytokines ,Regression Analysis ,Female ,Tumor necrosis factor alpha ,Bone marrow ,business ,Cell Division - Abstract
Labeling index (LI), apoptosis, levels of 2 pro-apoptotic cytokines tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta(TGF-beta), and the number of monocyte/macrophage cells that are the likely source of the cytokines were simultaneously measured in plastic-embedded bone marrow (BM) biopsy sections of 145 patients with myelodysplastic syndromes (MDS). TNF-alpha was correlated with TGF-beta (P = .001) and with monocyte/macrophage cells (P = .003). Patients with excess blasts in their marrows had a higher TGF-beta level (P = .01) and monocyte/macrophage number (P = .05). In a linear regression model,TGF-beta emerged as the most significant biological difference between patients who have excess of blasts and those who do not (P = .01). We conclude that in addition to TNF-alpha, TGF-beta also plays a significant role in the initiation and pathogenesis of MDS, and that a more precise definition of its role will likely identify better preventive and therapeutic strategies.
- Published
- 2002
10. Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes
- Author
-
Naomi Galili, Shalini Anthwal, Sairah Alvi, Diya Dutt, Malihi Shaikh, Vilasini Shetty, Samia Suleman, Poluru L. Reddy, Aaron York, Shaista Y. Kamal, Suneel D. Mundle, Azra Raza, Saleem Dar, Gurveen Saberwal, and Krishnan Allampallam
- Subjects
Mutation ,Mutation rate ,Myelodysplastic syndromes ,Buccal swab ,Hematology ,Biology ,Gene mutation ,medicine.disease_cause ,medicine.disease ,Molecular biology ,Haematopoiesis ,Apoptosis ,hemic and lymphatic diseases ,medicine ,Gene - Abstract
Mitochondria (mt) play an important role in both apoptosis and haem synthesis. The present study was conducted to determine DNA mutations in mitochondrial encoded cytochrome c-oxidase I and II genes. Bone marrow (BM) biopsy and aspirate, peripheral blood (PB) and buccal smear samples were collected from 20 myelodysplastic syndrome (MDS) patients and 10 age-matched controls. Cytochrome c-oxidase I (CO I) and II (CO II) genes were amplified using polymerase chain reaction and sequenced. CO I mutations were found in 13/20 MDS patients and the CO II gene in 2/10 normal and 12/20 MDS samples, irrespective of MDS subtype. Mutations were substitutional, deletional and insertional. CO I mutations were most common at nucleotide positions 7264 (25%) and 7289 (15%), and CO II mutations were most common at nucleotide positions 7595 (40%) and 7594 (30%), suggesting the presence of potential 'hot-spots'. Mutations were not found in buccal smears of MDS patients and were significantly higher in MDS samples compared with age-matched controls in all cell fractions (P < 0.05), with bone marrow high-density fraction (BMHDF) showing a higher mutation rate than other fractions (P < 0.05). MDS marrows showed higher levels of apoptosis than normal controls (P < 0.05), and apoptosis in BMHDF was directly related to cytochrome c-oxidase I gene mutations (P < 0.05). Electron microscopy revealed apoptosis affecting all haematopoietic lineages with highly abnormal, iron-laden mitochondria. These results suggest a role for mt-DNA mutations in the excessive apoptosis and resulting cytopenias of MDS patients.
- Published
- 2002
11. Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients
- Author
-
Vilasini Shetty, Fabiana Nascimben, Poluru L. Reddy, Azra Raza, Leena Joshi, Naomi Galili, Sairah Alvi, Bruce Dangerfield, Krishnan Allampallam, Ahmed Shaher, Seema Hussaini, and Suneel D. Mundle
- Subjects
Pathology ,medicine.medical_specialty ,Stromal cell ,medicine.diagnostic_test ,Myelodysplastic syndromes ,Hematology ,Biology ,medicine.disease ,Inclusion bodies ,Haematopoiesis ,medicine.anatomical_structure ,Biopsy ,Parenchyma ,medicine ,Bone marrow ,Ex vivo - Abstract
Transmission electron microscopic (TEM) studies have not been reported in bone marrow (BM) biopsies of patients with myelodysplastic syndromes (MDS) owing to failure to overcome the technical impediment of maintaining ultrastructural detail in decalcified tissue. Using a modified technique to physically separate pieces of bone from marrow tissue under a dissecting microscope, and embedding the material directly for TEM, ultrastructural studies were performed in 15 MDS patients and four normal BM biopsies. Biopsy tissue was also used to initiate long-term in vitro cultures and 12-week plates were sacrificed for TEM analysis. Features noted in freshly obtained decorticated tissue included an excessive apoptosis in both haematopoietic and stromal cells, ringed sideroblasts with iron-laden mitochondria and highly active, enormously increased phagocytosis. In addition, type IV nuclear inclusion body variants (NIB-v) and confronting cylindrical cisternae (CCC) were readily identified in up to 40% of stromal cells in vivo, providing an important footprint of a possible infectious agent in the pathology of MDS. Cultured stromal cells did not show excessive apoptosis and only 2-4% fibroblasts showed the presence of NIB-v or CCC, underscoring the artificial nature of ex vivo systems. We conclude that ultrastructure studies using decorticated tissue can be a powerful tool to investigate the biology and aetiology of a variety of haematopoietic disorders as it enables the direct examination of BM biopsies with their intimate stromal parenchymal cell associations preserved intact.
- Published
- 2002
12. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial
- Author
-
Olatoyosi Odenike, Richard A. Larson, Xavier Poiré, Poluru L. Reddy, Philip A. Dy, Wendy Stock, Walter M. Stadler, Kevin Shannon, Loren Joseph, Scott E. Smith, Ernesto Diaz-Flores, Emily Curran, Gregory Koval, Neil M. Iyengar, Sachdev P. Thomas, Mark Kirschbaum, Harry P. Erba, Ehab Atallah, Rangesh Kunnavakkam, Leslie Popplewell, Nitin Jain, Margaret Green, Austin Doyle, and Theodore Karrison
- Subjects
Oncology ,Neuroblastoma RAS viral oncogene homolog ,MAPK/ERK pathway ,Male ,Myeloid ,Cancer Research ,Administration, Oral ,medicine.disease_cause ,80 and over ,ras ,Cancer ,Aged, 80 and over ,Pediatric ,Leukemia ,MEK inhibitor ,Hematology ,Middle Aged ,Leukemia, Myeloid, Acute ,Proto-Oncogene Proteins c-kit ,medicine.anatomical_structure ,Treatment Outcome ,6.1 Pharmaceuticals ,Administration ,Female ,KRAS ,Oral ,Adult ,medicine.medical_specialty ,Childhood Leukemia ,Pediatric Cancer ,Oncology and Carcinogenesis ,Antineoplastic Agents ,Acute ,Article ,Rare Diseases ,Clinical Research ,Internal medicine ,medicine ,Genetics ,Humans ,Oncology & Carcinogenesis ,Protein Kinase Inhibitors ,Aged ,Mitogen-Activated Protein Kinase Kinases ,business.industry ,Evaluation of treatments and therapeutic interventions ,medicine.disease ,Genes, ras ,Genes ,fms-Like Tyrosine Kinase 3 ,Immunology ,Fms-Like Tyrosine Kinase 3 ,Mutation ,Selumetinib ,Benzimidazoles ,business - Abstract
Purpose: The clinical relevance of targeting the RAS/RAF/MEK/ERK pathway, activated in 70% to 80% of patients with acute myelogenous leukemia (AML), is unknown. Experimental Design: Selumetinib is an oral small-molecule inhibitor of MAP–ERK kinase (MEK)-1/2. Forty-seven patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study. Patients were stratified by FLT3 ITD mutation status. The primary endpoint was response rate (complete, partial, and minor). Leukemia cells were analyzed for extracellular signal—regulated kinase (ERK) and mTOR phosphorylation. Results: Common drug-related toxicities were grade 1–2 diarrhea, fatigue, nausea, vomiting, and skin rash. In the FLT3 wild-type cohort, six of 36 (17%) patients had a response [one partial response, three minor responses, two unconfirmed minor responses (uMR)]. No patient with FLT3 ITD responded. NRAS and KRAS mutations were detected in 7% and 2% of patients, respectively. The sole patient with KRAS mutation had uMR with hematologic improvement in platelets. Baseline p-ERK activation was observed in 85% of patients analyzed but did not correlate with a response. A single-nucleotide polymorphism (SNP) rs3733542 in exon 18 of the KIT gene was detected in significantly higher number of patients with response/stable disease compared with nonresponders (60% vs. 23%; P = 0.027). Conclusions: Selumetinib is associated with modest single-agent antileukemic activity in advanced AML. However, given its favorable toxicity profile, combination with drugs that target other signaling pathways in AML should be considered. The potential association of SNP rs3733542 in exon 18 of the KIT gene with antileukemic activity of selumetinib is intriguing, but will require validation in larger trials. Clin Cancer Res; 20(2); 490–8. ©2013 AACR.
- Published
- 2014
13. Successful establishment of long-term bone marrow cultures in 103 patients with myelodysplastic syndromes
- Author
-
Laurie Lisak, Suneel D. Mundle, Xiao-Ke Huang, Azra Raza, R. Z. Borok, Leena Joshi, Krishnan Allampallam, Bruce Dangerfield, Shalini Anthwal, Poluru L. Reddy, Ahmed Shaher, Sefer Gezer, Francesca Zorat, Leslie Little, Sairah Alvi, Naomi Galili, Benita Henderson, and Vilasini Shetty
- Subjects
Adult ,Cancer Research ,Pathology ,medicine.medical_specialty ,Stromal cell ,Cell Culture Techniques ,Antigens, CD34 ,Bone Marrow Cells ,Biology ,Stroma ,Adipocytes ,medicine ,Humans ,Cell Lineage ,Endothelium ,Aged ,Aged, 80 and over ,Confluency ,Macrophages ,Myelodysplastic syndromes ,Hematology ,Fibroblasts ,Middle Aged ,Fetal Blood ,medicine.disease ,Immunohistochemistry ,Coculture Techniques ,Hematopoiesis ,Endothelial stem cell ,Microscopy, Electron ,Haematopoiesis ,medicine.anatomical_structure ,Oncology ,Case-Control Studies ,Myelodysplastic Syndromes ,Cytogenetic Analysis ,Bone marrow ,Stromal Cells ,Stem cell ,Cell Division - Abstract
We used bone marrow biopsies instead of mononuclear cells to maintain long-term cultures from 103 patients belonging to all five sub-categories of myelodysplastic syndromes (MDS), as well as 12 normal controls. By week 4, 30-50% confluency was reached and could be maintained for up to 12 weeks with 100% confluency. The four prominent cells were fibroblasts, macrophages, endothelial cells and adipocytes. Immunohistochemical and electron microscopic studies provided lineage confirmation. Normal hematopoiesis was well supported by MDS stroma. Neither the FAB nor cytogenetics was co-related with the potency of growth. MDS stroma appears to be both morphologically and functionally normal.
- Published
- 2001
14. α-thalassemia subtyping and the detection of silent mutations by high-resolution fragment analysis and DNA sequencing*, **
- Author
-
Poluru L. Reddy, Lemuel J. Bowie, and Erica M. Nowak
- Subjects
COLD-PCR ,Genetics ,Silent mutation ,Inverse polymerase chain reaction ,General Medicine ,Biology ,Molecular biology ,Subtyping ,DNA sequencing ,law.invention ,Sequencing by ligation ,law ,A-DNA ,Polymerase chain reaction - Abstract
Background : Sets of polymerase chain reaction (PCR) primers were used that make it possible to study subtypes of the most prevalent mutations that cause α-thalassemia (−α3.7 deletions). These primers (Dev and C3, Dev and C9c) can be used in PCR to amplify regions that are characteristic of the three −α3.7 deletion subtypes (α3.7i, α3.7ii, α3.7iii). These subtypes are important because the type of α-chain deletion can affect the level of α-globin production. Methods and Results : The PCR products were screened using automated high-resolution electrophoresis on a DNA sequencer. Subtypes were then identified by automated DNA sequencing. During the screening for subtypes with high-resolution fragment analysis, new fragments were detected that were slightly different from the expected size. DNA sequencing of these fragments demonstrated the presence of three mutations that had not been described or fully characterized before. Conclusions : High-resolution fragment analysis is a convenient way to detect α-thalassemia subtypes, and DNA sequencing of silent mutations can lead to a better understanding of the cause of these mutations.
- Published
- 1998
15. Binding of nitric oxide to thiols and hemes in hemoglobin H: implications for α-thalassemia and hypertension
- Author
-
Steven Callistein, Poluru L. Reddy, and Lemuel J. Bowie
- Subjects
Hemolytic anemia ,Hemeprotein ,Chemistry ,Thalassemia ,Biochemistry (medical) ,Clinical Biochemistry ,medicine.disease ,Nitric oxide ,chemistry.chemical_compound ,Hemoglobinopathy ,Hemoglobin A ,Biochemistry ,Tetramer ,medicine ,Hemoglobin - Abstract
Our earlier studies suggested an association between α-thalassemia and hypertension. We postulated that this association might involve trapping of the vasodilator nitric oxide (NO) by hemoglobin (Hb). Hb A has recently been shown to carry NO on its sulfhydryl groups in addition to its hemes. In this report we studied the interaction of purified Hb H as well as Hb A with NO. The number of reactive sulfhydryls were determined spectrophotometrically with bis-dithionitrobenzoate. Spectral studies and nitrosothiol measurements after treatment with NO or nitrosothiols indicated that all eight reactive sulfhydryls of Hb H were capable of binding NO. Hb A, however, was only able to bind and transfer two molecules of NO per tetramer. These findings support the biochemical basis for the association between α-thalassemia and hypertension.
- Published
- 1997
16. Alpha Thalassemia and Its Impact on Other Clinical Conditions
- Author
-
Lemuel J. Bowie, Kenneth R. Beck, and Poluru L. Reddy
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,business.industry ,Biochemistry (medical) ,Clinical Biochemistry ,Alpha (ethology) ,Alpha-thalassemia ,Gene deletion ,medicine.disease ,hemic and lymphatic diseases ,Internal medicine ,Multiplex polymerase chain reaction ,medicine ,Globin ,business ,Potential mechanism - Abstract
Mild alpha thalassemia is the most prevalent genetic trait worldwide. We have recently developed a multiplex polymerase chain reaction method to screen for the most common deletions which give rise to alpha thalassemia. The authors have used this method to investigate a potential association of alpha thalassemia with hypertension. Our results show that the prevalence of hypertension in hospitalized blacks who have the -alpha 3.7 deletion is 71 percent higher than the prevalence in hospitalized blacks who do not have the deletion. The authors present a potential mechanism to explain this association.
- Published
- 1997
17. Sequence-Based Diagnosis of Hemoglobinopathies in the Clinical Laboratory
- Author
-
Poluru L. Reddy and Lemuel J. Bowie
- Subjects
Diagnostic information ,Hemoglobin electrophoresis ,business.industry ,Biochemistry (medical) ,Clinical Biochemistry ,Medicine ,Globin chain ,Base sequence ,Computational biology ,business ,DNA sequencing ,Sequence (medicine) - Abstract
Electrophoresis at alkaline and acid pH values is the most widely used method for screening for hemoglobinopathies in the clinical laboratory. Nevertheless, the method does not provide definitive diagnostic information for a number of hemoglobins. New automated DNA sequencing techniques make it possible to definitively identify mutations which cause hemoglobinopathies. Moreover these techniques take about the same time as it takes to perform hemoglobin electrophoresis and globin chain electrophoresis. Although the reagent cost is somewhat higher, the results are definitive.
- Published
- 1997
18. GFI1B, EVI5, MYB--additional genes that cooperate with the human BCL6 gene to promote the development of lymphomas
- Author
-
Poluru L. Reddy, Beverly W. Baron, Loren Joseph, Joseph M. Baron, John Anastasi, Linda Wolff, Michael J. Thirman, Kristen Wroblewski, and Juraj Bies
- Subjects
Genetically modified mouse ,Male ,Lymphoma, B-Cell ,Transgene ,Genetic Vectors ,PIM1 ,Cell Cycle Proteins ,Mice, Transgenic ,Biology ,Lymphoma, T-Cell ,Oncogene Proteins v-myb ,Article ,Insertional mutagenesis ,Mice ,immune system diseases ,hemic and lymphatic diseases ,Proto-Oncogene Proteins ,Animals ,Humans ,MYB ,RNA, Messenger ,Molecular Biology ,Gene ,GTPase-Activating Proteins ,Cell Biology ,Hematology ,BCL6 ,Molecular biology ,Immunohistochemistry ,DNA-Binding Proteins ,Gene Expression Regulation, Neoplastic ,Repressor Proteins ,Cell Transformation, Neoplastic ,Retroviridae ,Cancer research ,Proto-Oncogene Proteins c-bcl-6 ,Molecular Medicine ,Female ,Signal Transduction ,Transcription Factors - Abstract
The BCL6 gene, which is expressed in certain B- and T-cell human lymphomas, is involved with chromosomal rearrangements and mutations in a number of these neoplasms. Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors. We used retroviral insertional mutagenesis in transgenic mice expressing the human BCL6 transgene in order to identify genes that cooperate with BCL6 during lymphomatous transformation. We previously reported PIM1 as the most frequently recurring cooperating gene in this model. We now report three newly identified cooperating genes—GFI1B, EVI5, and MYB—that we identified in the lymphomas of retroviral-injected BCL6 transgenic mice (but not in retroviral-injected non-transgenic controls); mRNA and protein expression of GFI1B and EVI5 were decreased in the murine tumors, whereas MYB mRNA and protein expression were increased or decreased. These findings correlated with protein expression in human lymphomas, both B- and T-cell. Improved therapy of lymphomas may necessitate the development of combinations of drugs that target the alterations specific to each neoplasm.
- Published
- 2013
19. Effect of low pH treatment on opioid peptides binding to their receptors and functional coupling of G-proteins to adenylyl cyclase in the rat spinal cord
- Author
-
Hemendra N. Bhargava and Poluru L. Reddy
- Subjects
Male ,medicine.medical_specialty ,Enkephalin ,Physiology ,G protein ,Receptors, Opioid, mu ,Ethylketocyclazocine ,Biochemistry ,Rats, Sprague-Dawley ,Adenylyl cyclase ,Radioligand Assay ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Endocrinology ,GTP-Binding Proteins ,Opioid Receptor Binding ,Internal medicine ,medicine ,Animals ,Opioid peptide ,Receptor ,Analgesics ,Chemistry ,Receptors, Opioid, kappa ,Cell Membrane ,Enkephalins ,Enkephalin, Ala(2)-MePhe(4)-Gly(5) ,Hydrogen-Ion Concentration ,Spinal cord ,Rats ,Kinetics ,DAMGO ,medicine.anatomical_structure ,Spinal Cord ,Sodium Fluoride ,Adenylyl Cyclases - Abstract
Because low pH treatment is known to alter the coupling of G-proteins to brain receptors, and little is known about such an effect in the spinal cord, the present study was undertaken to examine whether preincubation of rat spinal cord membranes at low pH (pH 4.5) alters opioid receptor binding characteristics and sodium fluoride (NaF)-stimulated adenylyl cyclase (AC) activity (as a function of G s mediated). [ 3 H][ d -Ala 2 ,MePhe 4 ,Gly-ol]enkephalin (DAMGO) and [ 3 H]ethylketocyclazosine (EKC) were used to label μ- and κ-opioid receptors, respectively. AC activity was determined using ATP as substrate and cAMP formed was quantified. Low pH treatment of membranes did not affect the μ- and κ-opioid binding characteristics in rat spinal cord. However, the low pH treatment significantly reduced the NaF-stimulated AC activity in rat spinal cord. It is concluded that low pH treatment causes selective changes in the functional coupling of G s -proteins to AC without affecting the opioid receptor binding characteristics in the spinal cord.
- Published
- 1996
20. Down-regulation of N-methyl-d-aspartate (NMDA) receptors of brain regions and spinal cord of rats treated chronically with morphine
- Author
-
Poluru L. Reddy, Hemendra N. Bhargava, and Krishnamurthy P. Gudehithlu
- Subjects
Male ,medicine.medical_specialty ,Central nervous system ,Glycine ,Down-Regulation ,Glutamic Acid ,Hippocampus ,Striatum ,Receptors, N-Methyl-D-Aspartate ,Rats, Sprague-Dawley ,Internal medicine ,medicine ,Animals ,Brain Chemistry ,Pharmacology ,Morphine ,Chemistry ,Glutamate receptor ,Spinal cord ,Rats ,Endocrinology ,medicine.anatomical_structure ,Spinal Cord ,Hypothalamus ,Anesthesia ,NMDA receptor ,Dizocilpine Maleate ,Morphine Dependence ,medicine.drug - Abstract
1. The effects of morphine tolerance and abstinence on the characteristics of N-methyl-D-aspartate (NMDA) receptors, labeled with [3H]MK-801, were determined in the brain regions and spinal cord of the rat. 2. Male Sprague-Dawley rats were rendered tolerant to and physically dependent on morphine by subcutaneous implantation of six morphine pellets during a 7-day period. In tolerant (non-abstinent) rats, the pellets were left intact at the time of sacrificing, whereas in the abstinent rats the pellets were removed 16 hr prior to sacrificing. 3. The binding of [3H]MK-801, an NMDA receptor antagonist, to membranes prepared from spinal cord and brain regions (cortex, striatum, amygdala, hippocampus, hypothalamus, midbrain and pons-medulla) was determined using 5 nM concentration of the ligand in the presence of 30 microM glycine and 50 microM of glutamate. 4. In non-abstinent morphine tolerant rats, the binding of [3H]MK-801 was decreased by 40 and 33% in the midbrain and spinal cord, respectively, in comparison with their placebo controls. In morphine abstinent rats, the binding of [3H]MK-801 was decreased by 42, 29 and 50% in hypothalamus, midbrain and spinal cord, respectively, in comparison with their placebo controls. The binding of [3H]MK-801 to other brain regions and spinal cord of morphine tolerant and abstinent rats did not differ from their respective placebo controls. 5. Thus, these studies demonstrate, for the first time, that in the presence of glutamate and glycine, NMDA receptors of selected brain regions and spinal cord are down-regulated in rats treated chronically with morphine.
- Published
- 1995
21. PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas
- Author
-
Kristen Wroblewski, John Anastasi, Loren Joseph, Beverly W. Baron, Jingfang Dong, Poluru L. Reddy, Joseph M. Baron, Juraj Bies, Linda Wolff, Elizabeth Hyjek, and Michael J. Thirman
- Subjects
Lymphoma ,Transgene ,Mutagenesis (molecular biology technique) ,PIM1 ,Mice, Transgenic ,Biology ,Mice ,Proto-Oncogene Proteins c-pim-1 ,immune system diseases ,hemic and lymphatic diseases ,medicine ,Animals ,Humans ,RNA, Messenger ,Gene ,Regulation of gene expression ,Multidisciplinary ,Biological Sciences ,medicine.disease ,BCL6 ,Molecular biology ,Survival Analysis ,DNA-Binding Proteins ,Gene Expression Regulation, Neoplastic ,Mutagenesis, Insertional ,Retroviridae ,Cancer research ,Proto-Oncogene Proteins c-bcl-6 ,REL ,Precancerous Conditions - Abstract
Diffuse large B-cell lymphomas in humans are associated with chromosomal rearrangements (∼40%) and/or mutations disrupting autoregulation (∼16%) involving the BCL6 gene. Studies of lymphoma development in humans and mouse models have indicated that lymphomagenesis evolves through the accumulation of multiple genetic alterations. Based on our prior studies, which indicated that carcinogen-induced DNA mutations enhance the incidence of lymphomas in our mouse model expressing a human BCL6 transgene, we hypothesized that mutated genes are likely to play an important cooperative role in BCL6 -associated lymphoma development. We used retroviral insertional mutagenesis in an effort to identify which genes cooperate with BCL6 in lymphomagenesis in our BCL6 transgenic mice. We identified PIM1 as the most frequently recurring cooperating gene in our murine BCL6-associated lymphomas (T- and B-cell types), and we observed elevated levels of PIM1 mRNA and protein expression in these neoplasms. Further, immunohistochemical staining, which was performed in 20 randomly selected BCL6-positive human B- and T-cell lymphomas, revealed concurrent expression of BCL6 and PIM1 in these neoplasms. As PIM1 encodes a serine/threonine kinase, PIM1 kinase inhibition may be a promising therapy for BCL6/PIM1-positive human lymphomas.
- Published
- 2012
22. Brain and spinal cord kappa opiate receptors and pharmacological responses to U-50,488H in rats of differing ages
- Author
-
Veeranna, Hemendra N. Bhargava, George A. Matwyshyn, and Poluru L. Reddy
- Subjects
Male ,Agonist ,Aging ,medicine.medical_specialty ,Pyrrolidines ,medicine.drug_class ,Clinical Biochemistry ,Analgesic ,Central nervous system ,Ethylketocyclazocine ,Toxicology ,Binding, Competitive ,Biochemistry ,κ-opioid receptor ,Body Temperature ,Rats, Sprague-Dawley ,Behavioral Neuroscience ,Internal medicine ,medicine ,Animals ,Receptor ,Biological Psychiatry ,Brain Chemistry ,Pharmacology ,Analgesics ,business.industry ,Receptors, Opioid, kappa ,3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer ,Brain ,Spinal cord ,Rats ,medicine.anatomical_structure ,Endocrinology ,Spinal Cord ,Anesthesia ,Opiate ,business ,Kappa - Abstract
The analgesic and hypothermic responses to U-50,488H (25 mg/kg IP), a kappa opiate receptor agonist, were determined in male Sprague-Dawley rats aged 4, 8, and 24 weeks. In addition, the characteristics of the binding of [3H]ethylketocylazocine (EKC) to kappa opiate receptors in whole brain and spinal cord of rats of three age groups were also determined. Administration of U-50,488H produced an age-related increase in the analgesic response in the rat, i.e., the older rats exhibited a higher intensity of analgesic response than the younger rats. U-50,488H also produced a hypothermic response. The response in 4- and 24-week-old rats was similar, but that in 8-week-old rats was smaller than the rats in the other two age groups. [3H]EKC bound to whole brain and spinal cord membranes of rats at a single high affinity site. The Bmax value of [3H]EKC in the brain and spinal cord of 24-week-old rats was significantly lower than in 4- and 8-week-old rats; however, the Kd values did not differ. It is concluded that kappa opiate receptor agonist produces age-related increase in its analgesic response and that such effects are not related to the characteristics of kappa receptors in the brain and spinal cord.
- Published
- 1994
23. Effect of morphine tolerance and abstinence on the binding of [3H]MK-801 to brain regions and spinal cord of the rat
- Author
-
Hemendra N. Bhargava, Krishnamurthy P. Gudehithlu, and Poluru L. Reddy
- Subjects
Male ,medicine.medical_specialty ,Central nervous system ,Glycine ,Down-Regulation ,Glutamic Acid ,Receptors, N-Methyl-D-Aspartate ,Rats, Sprague-Dawley ,Glutamates ,Drug tolerance ,Internal medicine ,medicine ,Animals ,Molecular Biology ,Morphine ,Chemistry ,General Neuroscience ,Glutamate receptor ,Brain ,Drug Tolerance ,Spinal cord ,Rats ,Substance Withdrawal Syndrome ,Dizocilpine ,Endocrinology ,medicine.anatomical_structure ,Spinal Cord ,Cerebral cortex ,Anesthesia ,NMDA receptor ,Neurology (clinical) ,Dizocilpine Maleate ,Morphine Dependence ,Developmental Biology ,medicine.drug - Abstract
The effect of chronic administration of morphine to rats on the N-methyl-D-aspartate (NMDA) receptors labeled with [3H]MK-801, a non-competitive antagonist, was determined in brain regions and spinal cord. Male Sprague-Dawley rats were rendered tolerant to and physically dependent on morphine by subcutaneous implantation of 6 morphine pellets during a 7-day period. Each pellet contained 75 mg of morphine free base. Animals serving as controls were similarly implanted with placebo pellets. This procedure resulted in the development of a high degree of tolerance and physical dependence on morphine. Two sets of rats were used. In one, the pellets were left intact at the time of sacrifice (tolerant) and in the other the pellets were removed 16 h prior to sacrificing (abstinent). The binding constants, Bmax and Kd values of [3H]MK-801 were determined in cortex, hippocampus, hypothalamus, corpus striatum, midbrain and spinal cord. In the absence of glycine and glutamate, [3H]MK-801 bound to tissue membranes at a single high affinity site. The Bmax and Kd values of [3H]MK-801 were not altered in any of the tissues of the morphine abstinent rats. The Bmax value of [3H]MK-801 was significantly decreased in cerebral cortex of morphine tolerant rats as compared to their placebo controls but the Kd values did not change. In other brain regions and spinal cord of morphine tolerant rats and their placebo controls, the Bmax and Kd values of [3H]MK 801 did not differ.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1994
24. Effects of naltrexone on the binding of [3H]D-Ala2, MePhe4, Gly-ol5-enkephalin to brain regions and spinal cord and pharmacological responses to morphine in the rat
- Author
-
George A. Matwyshyn, Poluru L. Reddy, Hemendra N. Bhargava, and Veeranna
- Subjects
Male ,Enkephalin ,Central nervous system ,Receptors, Opioid, mu ,Pharmacology ,Naltrexone ,Body Temperature ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Animals ,Medicine ,Drug Implants ,Analgesics ,Morphine ,business.industry ,Narcotic antagonist ,Brain ,Enkephalins ,Enkephalin, Ala(2)-MePhe(4)-Gly(5) ,Spinal cord ,Rats ,Up-Regulation ,DAMGO ,medicine.anatomical_structure ,Spinal Cord ,chemistry ,Hypothalamus ,business ,medicine.drug - Abstract
1. 1. The effects of naltrexone pellet implantation and removal on the analgesic and hypothermic effects of morphine and the binding of 3 H- d -Ala 2 , MePhe 4 , Gly-ol 5 -enkephalin (DAMGO) to μ-opiate receptors in rat brain regions and spinal cord were determined. 2. 2. Male Sprague-Dawley rats were implanted subcutaneously with a pellet containing 10 mg of naltrexone for 7 days. Placebo pellet implanted rats served as controls. The pellets were removed on day 8, and the analgesic and hyperthermic effects were determined in the rat 24 hr later. Morphine produced a dose-dependent analgesic and hyperthermic responses in rats implanted with placebo pellets. Enhanced analgesic and hyperthermic responses to morphine were produced in rats implanted with naltrexone pellets. 3. 3. The binding constants ( B max and K d values) of [ 3 H]DAMGO in regions of the brain (amygdala, hypothalamus, striatum, midbrain, hippocampus, pons + medulla and cortex), and spinal cord of rats with naltrexone pellet left intact or removed were determined. The B max values of [ 3 H]DAMGO were increased in all brain regions and spinal cord of rats in which the naltrexone pellets were left in place or removed prior to sacrificing. However, the K d values of [ 3 H]DAMGO were unaffected by naltrexone treatment. 4. 4. It is concluded that enhanced analgesic and hyperthermic response to morphine is produced in rats implanted with naltrexone pellets and such alterations in the pharmacological responses are due to up-regulation of μ-opiate receptors in all the brain regions and spinal cord. Additionally whether the pellets were left intact (receptors blocked) or removed (receptors not blocked), the μ-opiate receptors were up-regulated in spinal cord and all the regions of the brain.
- Published
- 1993
25. Evidence for the behavioral supersensitivity of dopamine D2 receptors without receptor up-regulation in morphine-abstinent rats
- Author
-
Hemendra N. Bhargava, Poluru L. Reddy, Veeranna, and Sanjay N. Thorat
- Subjects
Male ,Agonist ,medicine.medical_specialty ,medicine.drug_class ,Central nervous system ,Physical dependence ,Striatum ,Body Temperature ,Rats, Sprague-Dawley ,Dopamine ,Internal medicine ,Dopamine receptor D2 ,medicine ,Animals ,Receptor ,Molecular Biology ,Bromocriptine ,Brain Chemistry ,Behavior, Animal ,Receptors, Dopamine D2 ,Chemistry ,General Neuroscience ,Drug Tolerance ,Rats ,Substance Withdrawal Syndrome ,Up-Regulation ,Kinetics ,medicine.anatomical_structure ,Endocrinology ,Spinal Cord ,Spiperone ,Morphine ,Neurology (clinical) ,medicine.symptom ,Morphine Dependence ,Developmental Biology ,medicine.drug - Abstract
The effect of morphine tolerance-dependence and abstinence on the characteristics of dopamine D 2 receptors in brain regions and spinal cord was determined in the rat. Male Sprague-Dawley rats were implanted s.c. under light ether anesthesia with 6 morphine pellets for a 7-day period, each containing 75 mg of morphine free base. Rats implanted with placebo served as controls. This procedure resulted in the development of tolerance to morphine as evidenced by decreased analgesic response to a challenge dose of morphine. Similarly, the development of physical dependence was evidenced by a decreased in body weight and colonic temperature after morphine pellet removal (withdrawal). The binding characteristics ( B max and K d values) of [ 3 H]spiroperidol to dopamine D 2 receptors were determined in the tissues of morphine-tolerant and morphine-abstinent rats. In the tolerant rats, the pellets were left intact at the time of sacrificing, whereas, in the abstinent rats the pellets were removed 18 h prior to sacrificing. The binding of [ 3 H]spiroperidol was determined in membranes prepared from brain regions (hypothalamus, hippocampus, cortex, pons and medulla, midbrain, corpus striatum and amygdala) and spinal cord of rats from various treatment groups. [ 3 H]Spiroperidol bound to brain regions and spinal cord at a single high affinity site. The B max or the K d values in brain regions and spinal cord of morphine-tolerant and -abstinent rats did not differ from their respective placebo controls. The behavioral responses to a selective dopamine D 2 receptor agonist, 2-bromo-α-ergocryptine were also determined in the morphine-abstinent rats. In morphine-abstinent rats, increased behavioral activity, such as total distance travelled, number of movements, and the number of stereotypic movements was seen as compared to placebo controls. The dose of 2-bromo-α-ergocryptine which by itself had no effect on any type of behavioral activity in placebo-treated rats, increased the total distance travelled, horizontal activity, number of movements, and movement time in morphine-abstinent rats. Although in morphine-tolerant or morphine-abstinent rats, the characteristics of [ 3 H]spiroperidol binding to dopamine D 2 receptors in brain regions and spinal cord were unchanged, the supersensitivity was observed to behavioral responses of 2-bromo-α-ergocryptine, a selective dopamine D 2 receptor agonist. These results provide an evidence for behavioral responses of 2-bromo-α-ergocryptine, a selective up-regulation in morphine abstinent rats. Previously, we have show that dopamine D 1 receptors are unaffected in morphine tolerant rats but are modified in morphine-abstinent rats. Thus, in the morphine abstinent process a significant difference was noted in the biochemical characteristics of dopamine D 1 and D 2 receptors.
- Published
- 1993
26. COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma
- Author
-
Loren Joseph, Colin C. Pritchard, Jonathan F. Tait, Laura Akagi, and Poluru L. Reddy
- Subjects
COLD-PCR ,Histology ,Standard of care ,biology ,Colorectal cancer ,business.industry ,Diagnostic accuracy ,medicine.disease ,medicine.disease_cause ,Bioinformatics ,digestive system diseases ,Melting curve analysis ,Pathology and Forensic Medicine ,Technical Advance ,medicine ,Cancer research ,biology.protein ,lcsh:Pathology ,In patient ,KRAS ,Epidermal growth factor receptor ,business ,lcsh:RB1-214 - Abstract
Background KRAS mutational analysis is the standard of care prior to initiation of treatments targeting the epidermal growth factor receptor (EGFR) in patients with metastatic colorectal cancer. Sensitive methods are required to reliably detect KRAS mutations in tumor samples due to admixture with non-mutated cells. Many laboratories have implemented sensitive tests for KRAS mutations, but the methods often require expensive instrumentation and reagents, parallel reactions, multiple steps, or opening PCR tubes. Methods We developed a highly sensitive, single-reaction, closed-tube strategy to detect all clinically significant mutations in KRAS codons 12 and 13 using the Roche LightCycler® instrument. The assay detects mutations via PCR-melting curve analysis with a Cy5.5-labeled sensor probe that straddles codons 12 and 13. Incorporating a fast COLD-PCR cycling program with a critical denaturation temperature (Tc) of 81°C increased the sensitivity of the assay >10-fold for the majority of KRAS mutations. Results We compared the COLD-PCR enhanced melting curve method to melting curve analysis without COLD-PCR and to traditional Sanger sequencing. In a cohort of 61 formalin-fixed paraffin-embedded colorectal cancer specimens, 29/61 were classified as mutant and 28/61 as wild type across all methods. Importantly, 4/61 (6%) were re-classified from wild type to mutant by the more sensitive COLD-PCR melting curve method. These 4 samples were confirmed to harbor clinically-significant KRAS mutations by COLD-PCR DNA sequencing. Five independent mixing studies using mutation-discordant pairs of cell lines and patient specimens demonstrated that the COLD-PCR enhanced melting curve assay could consistently detect down to 1% mutant DNA in a wild type background. Conclusions We have developed and validated an inexpensive, rapid, and highly sensitive clinical assay for KRAS mutations that is the first report of COLD-PCR combined with probe-based melting curve analysis. This assay significantly improved diagnostic accuracy compared to traditional PCR and direct sequencing.
- Published
- 2010
27. Clinical Utility of the Detection of Genomic Aberrations in Formalin-Fixed Paraffin-Embedded Myeloid Sarcoma Samples
- Author
-
Madina Sukhanova, Kenan Onel, Loren Joseph, Poluru L. Reddy, Zejuan Li, Mark M. Sasaki, Gordana Raca, Kamran M. Mirza, and Friedrich Stölzel
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Formalin fixed paraffin embedded ,Genetics ,medicine ,Myeloid sarcoma ,Biology ,medicine.disease ,Molecular Biology - Published
- 2013
28. Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes
- Author
-
Poluru L, Reddy, Vilasini T, Shetty, Diya, Dutt, Aaron, York, Saleem, Dar, Suneel D, Mundle, Krishnan, Allampallam, Sairah, Alvi, Naomi, Galili, Gurveen Sethi, Saberwal, Shalini, Anthwal, Malihi, Shaikh, Samia, Suleman, Shaista Y, Kamal, and Azra, Raza
- Subjects
Adult ,Aged, 80 and over ,Male ,Apoptosis ,Bone Marrow Cells ,Middle Aged ,DNA, Mitochondrial ,Mitochondria ,Electron Transport Complex IV ,Myelodysplastic Syndromes ,Mutation ,In Situ Nick-End Labeling ,Humans ,Female ,Aged - Abstract
Mitochondria (mt) play an important role in both apoptosis and haem synthesis. The present study was conducted to determine DNA mutations in mitochondrial encoded cytochrome c-oxidase I and II genes. Bone marrow (BM) biopsy and aspirate, peripheral blood (PB) and buccal smear samples were collected from 20 myelodysplastic syndrome (MDS) patients and 10 age-matched controls. Cytochrome c-oxidase I (CO I) and II (CO II) genes were amplified using polymerase chain reaction and sequenced. CO I mutations were found in 13/20 MDS patients and the CO II gene in 2/10 normal and 12/20 MDS samples, irrespective of MDS subtype. Mutations were substitutional, deletional and insertional. CO I mutations were most common at nucleotide positions 7264 (25%) and 7289 (15%), and CO II mutations were most common at nucleotide positions 7595 (40%) and 7594 (30%), suggesting the presence of potential 'hot-spots'. Mutations were not found in buccal smears of MDS patients and were significantly higher in MDS samples compared with age-matched controls in all cell fractions (P0.05), with bone marrow high-density fraction (BMHDF) showing a higher mutation rate than other fractions (P0.05). MDS marrows showed higher levels of apoptosis than normal controls (P0.05), and apoptosis in BMHDF was directly related to cytochrome c-oxidase I gene mutations (P0.05). Electron microscopy revealed apoptosis affecting all haematopoietic lineages with highly abnormal, iron-laden mitochondria. These results suggest a role for mt-DNA mutations in the excessive apoptosis and resulting cytopenias of MDS patients.
- Published
- 2002
29. Blood pressure changes after intravenous administration of cell-free hemoglobin A and hemoglobin H in the rat
- Author
-
Poluru L. Reddy, Lemuel J. Bowie, and Hongsi Jiang
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Mean arterial pressure ,endocrine system diseases ,Physiology ,Clinical Biochemistry ,Alpha (ethology) ,Vasodilation ,Blood Pressure ,Alpha-thalassemia ,Biochemistry ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Infusions, Intravenous ,Heme ,Analysis of Variance ,Hemoglobin H ,Chemistry ,nutritional and metabolic diseases ,Hemoglobin A ,medicine.disease ,Rats ,Blood pressure ,Endocrinology ,Anesthesia ,Hemoglobin - Abstract
Hemoglobin H (HbH) is a tetramer of four beta chains (present in erythrocytes of alpha thalassemia), whereas hemoglobin A is a tetramer of two alpha and two beta chains. Since HbH is known to bind four times more nitric oxide (a vasodilator) at its sulfhydryls compared to HbA, the present studies were conducted to see the effect of HbH and HbA on rat blood pressure. The acute administration (20-2000 nmol/kg) of both HbH and HbA produced a dose-dependent effect on blood pressure. The net change in mean arterial pressure was significantly higher with HbH compared to HbA. Partially nitrosylated (in which SH groups are occupied with NO) HbH retained the property of raising blood pressure to some extent while HbA lost this property. Completely nitrosylated (in which both heme and SH groups are occupied with NO) derivatives of both HbH and HbA reduced the blood pressure to the same extent. The preliminary studies with chronic administration of HbA and HbH resulted in nonsignificant increase in blood pressure. It is concluded that these findings may explain the earlier observations of increased risk of hypertension in individuals with alpha thalassemia.
- Published
- 2000
30. Peripheral benzodiazepine receptors are decreased during cocaine withdrawal in humans
- Author
-
Poluru L. Reddy, John M. Davis, Subhash C. Pandey, Javaid I. Javaid, Ghanshyam N. Pandey, and Michael P. Notorangelo
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adult male ,Neutrophils ,media_common.quotation_subject ,Metabolite ,Pharmacology ,chemistry.chemical_compound ,Radioligand Assay ,Cocaine ,Dopamine ,Internal medicine ,medicine ,Humans ,Biological Psychiatry ,media_common ,GABAA receptor ,business.industry ,Homovanillic acid ,Homovanillic Acid ,Abstinence ,Middle Aged ,Receptors, GABA-A ,Pathophysiology ,Peripheral ,Substance Withdrawal Syndrome ,Kinetics ,Endocrinology ,chemistry ,business ,medicine.drug - Abstract
In the present study, homovanillic acid in plasma (pHVA) and benzodiazepine receptors (3H-PK11195 binding) in neutrophil membranes were determined in blood obtained from cocaine-dependent (DSM-III-R) adult male inpatients at baseline-(within 72 hr of last cocaine use) and after 3 weeks of cocaine abstinence, and normal controls. The mean (+/- SEM) pHVA at baseline (10.3 ng/ml +/- 1.1) was similar to normals and did not change after 3 weeks of cocaine abstinence. Similarly, the binding indices of benzodiazepine receptors in cocaine-dependent subjects as a group were not significantly different than in normal controls. In 10 cocaine-dependent subjects, however, where both blood samples were available, the number of 3H-PK11195 binding sites was significantly (p0.05) decreased after 3 weeks of cocaine abstinence (mean +/- sem: Bmax = 6371 +/- 657 fmol/mg protein) compared with baseline (Bmax = 7553 +/- 925 fmol/mg protein), although there were no differences in the binding affinity (mean +/- sem: KD = 8.6 +/- 1.2 nmol/L after 3 weeks of abstinence compared with 8.1 +/- 1.0 nmol/L at baseline). These preliminary results suggest that peripheral benzodiazepine receptors may play an important role in the pathophysiology of cocaine withdrawal in cocaine-dependent human subjects.
- Published
- 1994
31. Effect of morphine tolerance and abstinence on the binding of [3H]naltrexone to discrete brain regions and spinal cord of the rat
- Author
-
Veeranna, George A. Matwyshyn, Hemendra N. Bhargava, Poluru L. Reddy, and Sanjay N. Thorat
- Subjects
Agonist ,Male ,Enkephalin ,medicine.drug_class ,Receptors, Opioid, mu ,Pharmacology ,Naltrexone ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,medicine ,Animals ,Drug Implants ,Analgesics ,Membranes ,Morphine ,Chemistry ,Antagonist ,Brain ,Drug Tolerance ,Enkephalins ,Enkephalin, Ala(2)-MePhe(4)-Gly(5) ,Receptor antagonist ,Rats ,Substance Withdrawal Syndrome ,DAMGO ,Spinal Cord ,Receptors, Opioid ,Opiate ,Morphine Dependence ,medicine.drug - Abstract
1. The effect of morphine tolerance and abstinence on the binding of [ 3 H]naltrexone to discrete brain regions and spinal cord of the rat was determined. 2. Male Sprague-Dawley rats were implanted s.c. under light ether anesthesia with six morphine pellets for a 7-day period. Each pellet contained 75 mg of morphine base. Rats implanted with six placebo pellets each served as controls. 3. This procedure resulted in the development of tolerance to morphine as evidenced by decreased analgesic response to various doses of morphine. 4. The binding characteristics ( B max or K d values) of [ 3 H]naltrexone, an opiate receptor antagonist, were determined in various tissues of morphine tolerant and abstinent rats. In the tolerant rats, the pellets were left in place at the time of sacrificing, whereas in the abstinent rats, the pellets were removed 18 hr prior to sacrificing. 5. The binding of [ 3 H]naltrexone to opiate receptors on membranes prepared from brain regions (hypothalamus, hippocampus, cortex, pons and medulla, midbrain, corpus striatum and amygdala) and spinal cord of rats from various treatment groups was determined. 6. [ 3 H]Naltrexone bound to tissue membranes at a single high affinity binding sites. The B max values of [ 3 H]naltrexone to bind to opiate receptors on the membranes of amygdala and striatum were increased significantly in morphine tolerant rats when compared to the placebo controls, but the K d values did not differ. 7. The B max and K d values of [ 3 H]naltrexone did not differ in any other brain region or spinal cord of morphine tolerant rats and their placebo controls. The binding constants of [ 3 H]naltrexone were unaffected in morphine abstinent rats. 8. Previously we had shown that the binding of [ 3 H] d -Ala 2 , MePhe 4 , Gly-ol 5 enkephalin (DAMGO), a highly specific agonist for μ-opiate receptors was decreased in cortex, pons and medulla and spinal cord of morphine tolerant but not in the abstinent rats. In addition, δ and k receptors are unaffected in morphine tolerant and abstinent rats. 9. The results suggest that direction of change, as well as, the brain areas for μ-agonist and -antagonist opiate binding sites are affected differentially in morphine tolerant rats.
- Published
- 1994
32. Evaluation of MMR Concordance Based on Either International Scale (IS) or National Comprehensive Cancer Network (NCCN) Criteria Using Reconstructed 'Virtual' CML Patient Profiles From the REVEAL BCR-ABL Methods Comparison Study
- Author
-
Andre Mignault, Diego Ossa, Brian Manning, Christopher D. Watt, Sha-Sha Wang, Nicholas Potter, Holger Höfling, Paul Choppa, Feng Yang, Mike M. Moradian, Andrew M. Stein, Poluru L. Reddy, Michael M. Quigley, Meir Wetzler, and Brian Mullaney
- Subjects
Oncology ,Treatment response ,medicine.medical_specialty ,business.industry ,Concordance ,International scale ,Immunology ,Cancer ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Clinical trial ,Quartile ,Method comparison ,Major Molecular Response ,Internal medicine ,medicine ,business - Abstract
Abstract 3542 Background: Achieving major molecular response (MMR) is an important milestone in chronic myeloid leukemia (CML) therapy. MMR has been defined as a 3-log reduction in BCR-ABL transcript levels from a standardized baseline (BL) established in the IRIS trial (Hughes TP, N Engl J Med. 2003). Standardization has been achieved through the development of an IS, which defines MMR as BCR-ABLIS = 0.1%. In contrast, the NCCN defines MMR as a 3-log reduction in BCR-ABL transcript levels but is indefinite on the definition of BL. Here, using reconstructed samples emulating CML patient BCR-ABL levels, the pairwise concordance of MMR determination was examined within and between 3 labs using the IS-standardized GeneXpert® (GX) system and 3 labs using laboratory-developed tests (LDTs). For comparative purposes, this analysis assumes BL is established at the time of diagnosis. Methods: 100 virtual patients (VPs) were emulated based on data from the REVEAL BCR-ABL Methods Comparison Study, in which 8 discrete levels of blinded K562 cell–spiked blood corresponding to BCR-ABLIS ratios ranging from ∼10% to ∼0.01% were analyzed by 3 labs using the IS-standardized GX system and 3 labs using non-IS LDTs. VP emulations were guided by actual patient outcomes in landmark analyses of 7- treatment response (Hughes TP, Blood. 2010). Treatment response profiles over an 18-month time horizon were modeled by assigning one of the 8 BCR-ABL levels ranging from approximately 10%-0.01% IS sampled in the REVEAL study to each of 4 virtual time points (eg, 3, 6, 12, and 18 months). BL levels were selected from quartiles representing pretreatment BCR- ABL ratios between 50–150%; results based on BL levels observed in the IRIS clinical trial will also be presented. 600 VP transcript profiles (VTPs) were then reconstructed using data from each of the 6 laboratories for all 100 VPs. The final 18-month time point in each VTP provided the BCR-ABL level against which the IS or NCCN objective criterion was applied to make MMR determinations. MMR concordance was evaluated by inspecting all possible inter-lab pairwise comparisons among the 100 VPs. Results: Pairwise concordance in MMR as determined by NCCN criterion among all 6 labs is shown in Fig 1A. MMR determinations among the 3 GX labs were concordant in 88% to 93% of VPs. In contrast, MMR determinations among the LDTs were concordant in 43% to 80% of VPs, and MMR determinations were concordant in 53% to 91% of VPs when compared between GX labs and LDTs. When MMR determination based on IS criterion for GX was considered, MMR concordance improved to 93% to 96% among the GX labs in contrast to 51% to 92% concordance observed between the GX and LDT sites (Fig 1B). It is noteworthy that Lab D results more closely approximated the IS than results from the other LDTs examined in the REVEAL study (data not shown). Although Lab D does not report results per the IS, it does report results relative to a median diagnostic BL, similar to the approach used in the IRIS trial. A healthcare system based on LDTs without any attempted IS standardization resulted in MMR concordance of only 43%. Potential sources of discordance among tests will be discussed in detail. Conclusions: These results illustrate that the NCCN criterion for MMR determination is not adequate for inter-lab comparisons of BCR-ABL transcript levels near the clinically important level of MMR. In contrast, standardization to the IS improves inter-lab concordance in MMR determination. Taken together, these results highlight the discrepancies that may result when comparing molecular responses between labs not standardized to the IS. As attainment of MMR is a critical milestone of CML therapy, errors in MMR determination may have an adverse impact on CML disease management. Disclosures: Reddy: Novartis: Research Funding, as Presenting Author, sponsorship to attend ASH. Höfling:Novartis: Employment. Manning:Novartis: Employment. Mignault:Novartis: Employment. Mullaney:Novartis: Employment. Ossa:Novartis: Employment. Stein:Novartis: Employment. Wang:Novartis: Employment. Yang:Novartis: Employment.
- Published
- 2011
33. Evidence for the role of nitric oxide in kappa-opiate tolerance in mice
- Author
-
Hemendra N. Bhargava, Sanjay N. Thorat, and Poluru L. Reddy
- Subjects
Male ,Pyrrolidines ,Arginine ,Ratón ,Analgesic ,Pharmacology ,Nitric Oxide ,Nitric oxide ,chemistry.chemical_compound ,Mice ,medicine ,Animals ,Molecular Biology ,Analgesics ,omega-N-Methylarginine ,ATP synthase ,biology ,General Neuroscience ,Receptors, Opioid, kappa ,3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer ,Opiate tolerance ,Drug Tolerance ,Hypothermia ,Nitric oxide synthase ,chemistry ,Anesthesia ,biology.protein ,Neurology (clinical) ,Amino Acid Oxidoreductases ,medicine.symptom ,Nitric Oxide Synthase ,Developmental Biology - Abstract
The hypothesis that inhibition of nitric oxide (NO) synthase with subsequent decrease in the production of NO might attenuate the development of κ-opiate tolerance was examined. Concurrent treatment of NO synthase inhibitor, N G -monomethyl- l -arginine ( l -NMMA) (2–8 mg/kg, i.p.) along with U-50,488H (25 mg/kg, i.p.) twice daily for 4 days dose-dependently attenuated the development of tolerance to the analgesic and hypothermic effects of U-50,488H (25 mg/kg, i.p.). l -NMMA by itself did not modify the analgesic and hypothermic effects of acute administration of U-50,488H. A potential role for NO in the development of κ-opiate tolerance is suggested.
- Published
- 1993
34. Biochemical and behavioral studies on the interaction between mu- and kappa-opiate agonists in mice
- Author
-
Sanjay N. Thorat, Hemendra N. Bhargava, Veeranna, and Poluru L. Reddy
- Subjects
Agonist ,Male ,medicine.medical_specialty ,Pyrrolidines ,Enkephalin ,Ethylketocyclazocine ,medicine.drug_class ,Analgesic ,Receptors, Opioid, mu ,Mice, Inbred Strains ,Hypothermia ,chemistry.chemical_compound ,Mice ,Internal medicine ,medicine ,Animals ,Molecular Biology ,Drug Implants ,Analgesics ,Behavior, Animal ,Morphine ,business.industry ,General Neuroscience ,Receptors, Opioid, kappa ,3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer ,Brain ,Drug Tolerance ,Cross-tolerance ,DAMGO ,Endocrinology ,chemistry ,Spinal Cord ,Neurology (clinical) ,business ,Tail flick test ,Developmental Biology ,medicine.drug - Abstract
Male Swiss-Webster mice were rendered tolerant to morphine by subcutaneous implantation of a morphine pellet, each containing 75 mg morphine base, for 3 days. Mice implanted with placebo pellets served as controls. A high degree of tolerance to the analgesic effect of morphine developed as evidenced by decreased analgesic response to various doses of morphine. A selective κ-opiate agonist, U-50,488H (8, 16 and 32 mg/kg, i.p.) produced dose-dependent analgesic and hypothermic effects in mice implanted with placebo pellets. A significant decrease in the analgesic and hypothermic effects of U-50,488H was observed in morphine tolerant mice as compared to placebo-treated mice. Mice were rendered tolerant to U-50,488H by injecting the drug (25 mg/kg, i.p.) twice daily for 4 days. Vehicle injected mice served as controls. Tolerance to the analgesic and hypothermic effects of U-50,488H in mice injected chronically with the drug was evidenced by the decreases in the intensity of these responses when compared to those observed in vehicle injected controls. Morphine produced a dose-dependent analgesic and hypothermic effects in mice injected chronically with vehicle but the intensity of these effects was significantly lower in mice injected chronically with U-50,488H. These results indicate that a substantial tolerance to analgesic and hypothermic effects of U-50,488H develops in morphine tolerant mice. The effect of chronic injections of U-50,488H on the binding of [ 3 H]ethylketocyclazocine (EKC) and [ 3 H]D-Ala 2 ,MePhe 4 , Gly-ol 5 -enkephalin (DAMGO) to whole brain and spinal cord κ- and μ-opiate receptors was determined. Tolerance to U-50,488H was associated with down-regulation of κ-opiate receptors in the spinal cord where the K d value of [ 3 H]EKC was increased but the B max value did not change. On the other hand, μ-opiate receptors were increased in the brain but were decreased in the spinal cord. In both cases the changes in binding were due to alterations in the B max values of [ 3 H]DAMGO but the K d values did not change. Thus, biochemical and behavioral evidence is presented for the existence of cross-tolerance between μ- and κ-opiate agonists in mice.
- Published
- 1993
35. Effect of chronic administration of U-50,488H, a kappa-opioid receptor agonist, on central dopamine D2 receptors of the rat
- Author
-
Veeranna, Hemendra N. Bhargava, and Poluru L. Reddy
- Subjects
Agonist ,Male ,medicine.medical_specialty ,Pyrrolidines ,medicine.drug_class ,Central nervous system ,Striatum ,Rats, Sprague-Dawley ,Internal medicine ,Dopamine receptor D2 ,Medicine ,Animals ,Receptor ,Bromocriptine ,Pharmacology ,Analgesics ,Binding Sites ,Behavior, Animal ,business.industry ,Receptors, Dopamine D2 ,Receptors, Opioid, kappa ,3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer ,Brain ,Drug Tolerance ,Rats ,Up-Regulation ,Endocrinology ,medicine.anatomical_structure ,Spinal Cord ,Hypothalamus ,Spiperone ,Morphine ,business ,medicine.drug - Abstract
The effect of U-50,488H, a κ-opiate agonist, induced tolerance and abstinence on the characteristics of dopamine D2 receptors of brain regions and spinal cord was determined in the rat. Male Sprague-Dawley rats were injected with U-50,488H (25 mg/kg i.p) or its vehicle twice a day for 4 days. This procedure resulted in the development of tolerance to the analgesic activity of U-50,488H. The binding characteristics (Bmax and Kd values) of [3H]spiroperidol to dopamine D2 receptors were determined in discrete brain regions (hypothalamus, hippocampus, cortex, pons and medulla, midbrain, corpus striatum and amygdala) and spinal cord of U-50,488H-tolerant and -abstinent rats. Rats labeled as tolerant to U-50,488H were injected with U-50,488H on day 5 and killed 1 h later, whereas those labeled abstinent were killed on day 5 without the injection of the drug. Vehicle-injected rats served as controls. [3H]Spiroperidol bound to brain regions and spinal cord membranes at a single high affinity site. The Bmax and Kd values of [3H]spiroperidol in brain regions and spinal cord of U-50,488H-tolerant and abstinent rats did not differ from their respective vehicle-injected controls. The behavioral responses (total distance travelled, horizontal activity, movement time, total number of movements, number of stereotypic movements, stereotypic time and rest time) to different doses of a selective dopamine D2 receptor agonist, 2-bromo-α-ergocryptine (bromocriptine) were also determined in rats treated chronically with U-50,488H. A dose of 5 mg/kg of bromocriptine did not affect the behavioral responses, however, 15 and 30 mg/kg doses enhanced many behaviors in drug naive rats. Abstinence from U-50,488H did not modify any of the behavioral responses monitored. Bromocriptine (5 or 15 mg/kg) did not modify the behavior in rats chronically treated with U-50,488H. These results are in contrast to those observed for morphine where evidence was presented for the behavioral supersensitivity to bromocriptine in the absence of receptor up-regulation. These differences in the actions of morphine and U-50,488H on central dopamine D2 receptors may be partially responsible for their differential addiction liability.
- Published
- 1993
36. Phase II trial of sunitinib in medullary thyroid cancer (MTC)
- Author
-
K. B. Poluru, Victoria M. Villaflor, Ezra E.W. Cohen, E. E. Vokes, A. Zimrin, Jennifer Nam, Poluru L. Reddy, J.A. de Souza, Naifa L. Busaidy, and Tanguy Y. Seiwert
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Sunitinib ,medicine.medical_treatment ,Standard treatment ,Disease progression ,Medullary thyroid cancer ,medicine.disease ,Radiation therapy ,Multikinase inhibitor ,Internal medicine ,Medicine ,In patient ,business ,Serum calcitonin ,medicine.drug - Abstract
5504 Background: There is no standard treatment for MTC not amenable to surgery or radiotherapy. Sunitinib is an oral multikinase inhibitor against RET, VEGFR2, PDGFR, and c-KIT. We conducted an open-label multicenter phase II trial to determine the efficacy of sunitinib in patients (pts) with MTC and whether RET mutations can predict response. Methods: Pts with MTC who had evidence of disease progression within the prior 6 months and were not amenable to surgery or radiotherapy were treated with sunitinib 50 mg at a 4/2 week schedule. Responses were monitored by RECIST and serum calcitonin measurements every 12 weeks. Results: 25 pts were enrolled from 11/2006 to 08/2009; one pt was deemed ineligible and never received drug. Median follow-up was 11 months (range, 1-34); median age was 51 years (23-74); 12 pts (50%) were male. 23 pts were evaluable for response. To date, RET activating mutations were found in 11 (85%) of 13 analyzed tumors (8 somatic and 3 germline). Partial response (PR) was achieved in ...
- Published
- 2010
37. Arsenic Trioxide (Trisenox®) with/without Thalidomide in Patients with Myelodysplastic Syndromes (MDS) Produces Hematologic Improvement (HI)
- Author
-
Samreen Akbar, Khalid Washeed, Naomi Galili, Azra Raza, Jennifer Billmeier, Mohammad Mumtaz, Laurie Lisak, and Poluru L. Reddy
- Subjects
medicine.medical_specialty ,business.industry ,Myelodysplastic syndromes ,Immunology ,Karyotype ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Loading dose ,Gastroenterology ,Surgery ,Clinical trial ,Thalidomide ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Complex Karyotype ,Medicine ,Platelet ,Arsenic trioxide ,business ,medicine.drug - Abstract
In a previous clinical trial, we have shown that 7/28 MDS patients, belonging to IPSS intermediate and high risk categories, responded to a combination of Trisenox® and thalidomide including a complete hematologic and cytogenetic remission. Two trilineage responses were seen in patients with inv(3) abnormality. It was not clear whether the responses were due to the combination or to either drug alone. In the present study, we treated 30 MDS patients with Trisenox® (5 days of loading dose at 0.25mg/kg IV over 2 hours followed by twice weekly dose) for 6 months followed by the addition of thalidomide (100mg po qday x 3 months). The Median age was 71 years (19 males, 11 females). FAB types: RA 3 patients, RARS 2, RAEB 14, RAEB-t 8, CMMoL 2, Unclassified 1. IPSS: Low 0 patients, Int-1 10, Int-2 7, High 13. Two, 1,1 and 4 patients had abnormalities affecting chromosomes 5, 7, 8, and 20, while 12 patients showed a complex karyotype. Therapy was fairly well tolerated and median number of cycles was 3. Five patients showed a variety of hematologic responses as judged by the IWG criteria (1 trilineage, 1 cytogenetic and change in FAB type due to decrease in blasts, 1 ANC and reduction in blasts, and 2 with 50% reduction in blasts). Among the responders, 1 had 47 XX, +8(16 metaphases), del(X)(q22q25),del(3)(q25q27)(4 metaphases), 3 had a normal karyotype, and 1 had del(20q). Three of the partial responders were started on thalidomide, but all stopped within 2 months. Following response, the first patient showed disappearance of the clone bearing the chromosome 3 abnormality, confirming the sensitivity of these cells to Trisenox® as reported in our previous trial. Interestingly, 3/5 responders showed an increase in WBC/ANC and 1 in platelets as well (12, 22 and 90,000/ul), without any evidence of a differentiation syndrome. One also had an increase in platelets from ~50,000/ul to 966,000/ul. Blasts were 11, 24 and 28% in these 3 patients prior to therapy and decreased to 4, 6 and 24% respectively after treatment. It was concluded that the twice-daily dose of arsenic trioxide was well tolerated, and some patients converted their disease to a more myeloproliferative type picture.
- Published
- 2004
38. Genetic profiling of advanced RAI-resistant differentiated thyroid cancer and correlation with axitinib response
- Author
-
Sydeaka Watson, Poluru L. Reddy, Maria Luisa Carcangiu, Laura D. Locati, Lisa Licitra, Loren Joseph, Madhavi Nagilla, Angela Greco, Giuseppe Pelosi, Tanguy Y. Seiwert, Arun Khattri, Rebecca B. Schechter, and Ezra E.W. Cohen
- Subjects
Antitumor activity ,Axitinib ,Cancer Research ,Oncology ,business.industry ,VEGFR Inhibitor ,medicine ,Cancer research ,medicine.disease ,business ,Bioinformatics ,Thyroid cancer ,medicine.drug - Abstract
6066 Background: The VEGFR inhibitor axitinib has demonstrated compelling antitumor activity in advanced RAI-resistant differentiated thyroid cancer (DTC). Biomarkers predicting which patients may benefit from axitinib are unavailable. We aimed to describe molecular markers in DTC that correlate with clinical outcome to axitinib. Methods: Pretreatment FFPE thyroid cancer blocks from patients treated with axitinib were collected and genomic DNA was isolated. The OncoCarta Mutation Panel was used to test for 238 mutations. Copy number of VEGFR1-3 and PIK3CA was determined using qPCR. Genomic DNA was analyzed for coding regions of VEGFR1-3 with custom primers. Clinical response to axitinib, including best response (BR) (RECIST) and progression free survival (PFS), was ascertained from corresponding patients. Fisher’s exact test and logistic regression models were used to correlate BR with molecular findings. Cox proportional hazards regression was used to correlate PFS with molecular defects. Results: A total of 22 pathology samples (11 primary, 11 metastatic) were identified. In patients with 2 samples (n = 4), results were concordant and only included once for analysis. Of 18 specimens, 4 tumors (22%) harbored BRAF V600E mutations, 2 (11%) had KRAS mutations (G12A, G13D) and 2 (11%) had HRAS mutations (Q61R, Q61K). One sample with mutated KRAS also had a PIK3CA (H1047R) mutation. qPCR showed increased copy numbers of PIK3CA in 6 (33%) tumors, VEGFR1 in 0 (0%) tumors, VEGFR2 in 4 (22%) tumors, and VEGFR3 in 6 (33%) tumors. VEGFR sequencing showed a possibly damaging non-synonymous SNP in VEGFR2 (G539GR) in 2 samples (11%), a possibly damaging SNP in VEGFR3 (E350VE) in 1 sample (6%), and a potentially novel mutation in VEGFR2 (T439IT) in 2 samples (11%). No significant relationship was seen between BR or PFS and the presence of molecular defects. Conclusions: While DTC is genetically heterogenous, primary and metastatic lesions showed identical alterations. Molecular evaluation of DTC specimens did not predict clinical response to axitinib but data were limited by small sample size. We did identify molecular changes in VEGFR that should be further explored. This study was supported by Pfizer, Inc.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.